<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528085</url>
  </required_header>
  <id_info>
    <org_study_id>EWALL-PH-02</org_study_id>
    <secondary_id>2010-022855-46</secondary_id>
    <nct_id>NCT01528085</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
  <official_title>An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Nilotinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this trial is to evaluate the efficacy and the tolerance of the combination of
      nilotinib with chemotherapy in the front-line setting as induction and consolidation therapy
      in Ph+ ALL patient aged 55 years and over. A European consensus has been reached to adopt a
      common chemotherapeutic schedule for patients aged 55 years and over. This schedule will be
      used in this trial with the addition of nilotinib as concomitant therapy during induction,
      consolidation and maintenance. The patients will be prospectively monitored for minimal
      residual disease and bcr-abl tyrosine kinase domain mutations.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of efficacy of a nilotinib-based induction and consolidation therapy</measure>
    <time_frame>after 12 months</time_frame>
    <description>rate of patients without event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete haematological remission</measure>
    <time_frame>after induction treatment (week 5)</time_frame>
    <description>The rate of complete haematological remission after induction treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major molecular response in bone marrow</measure>
    <description>major molecular response defined by a BCR-ABL/ABL &lt; 0.1% in bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete molecular response</measure>
    <description>complete molecular response defined by a BCR-ABL/ABL &lt; 0.001% in bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>undetectable BCR-ABL level</measure>
    <description>The proportion of patients with confirmed undetectable BCR-ABL level with a test sensitivity of at least 4.5 log.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T315I or p-loop Mutations</measure>
    <description>Detection of a T315I or p-loop BCR-ABL TK domain mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>molecular relapse or progression</measure>
    <description>The proportion of patients with molecular relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <description>Tolerability as determined by descriptive assessment of adverse events and discontinuation due to treatment-related SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death during induction</measure>
    <time_frame>End of induction (week 5)</time_frame>
    <description>(all patients who started treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death in complete remission</measure>
  </secondary_outcome>
  <enrollment type="Actual">79</enrollment>
  <condition>Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)</description>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients &gt; 55 years

          2. Philadelphia chromosome- or BCR-ABL positive acute lymphoblastic leukemia

          3. Not previously treated except with corticosteroids or single dose vincristine (three
             doses cyclophosphamide accepted)

          4. With or without documented CNS involvement

          5. WHO performance status &lt; 2

          6. Normal serum levels &gt; LLN (lower limit of normal) of potassium, magnesium, total
             calcium corrected for serum albumin; or corrected to within normal limits with
             supplements, prior to the first dose of study medication

          7. Signed written inform consent

          8. Molecular evaluation for BCR-ABL performed

          9. Willingness of male subjects whose sexual partners are women of child-bearing
             potential (WOCBP), to use an effective form of contraception (pearl index &lt; 1%), such
             as complete sexual abstinence, combined oral contraceptive, hormone IUCD, vaginal
             hormone ring, transdermal contraceptive patch, contraceptive implant or depot
             contraceptive injection in combination with a second method of contraception like a
             condom or a cervical cap / diaphragm with spermicide or surgical sterilisation
             (vasectomy) in male patients during the study and at least 6 months thereafter. WOCBP
             are defined as sexually mature women who have not undergone a hysterectomy or surgical
             sterilization or who have not been naturally postmenopausal for at least 12
             consecutive months (i.e., who has had menses any time in the preceding 12 consecutive
             months).

        Exclusion Criteria:

          1. Patient previously treated with tyrosine kinase inhibitors

          2. Known impaired cardiac function, including any of the following:

               -  LVEF &lt; 45%

               -  Complete left bundle branch block

               -  Right bundle branch block plus left anterior hemiblock, bifascicular block

               -  Use of a ventricular-paced pacemaker

               -  Congenital long QT syndrome

               -  History of or presence of clinically significant ventricular or atrial
                  tachyarrhythmias

               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)

               -  QTcF&gt;450 msec on screening ECG. If QTc &gt; 450 msec and electrolytes are not within
                  normal ranges before nilotinib dosing, electrolytes should be corrected and then
                  the patient rescreened for QTcF criterion.

               -  Myocardial infarction with 12 months prior to starting nilotinib

               -  Other clinical significant heart disease (e.g. unstable angina, congestive heart
                  failure, uncontrolled hypertension)

          3. Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention

          4. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not
             mandatory) or known infection with Hepatitis B or C

          5. Treatment with any, other investigational agent or participating in another trial
             within 30 days prior to entering this study

          6. Inadequate hepatic functions defined as ASAT or ALAT &gt; 2,5 times the institutional
             upper limit of normal or &gt; 5 times ULN if considered due to leukemia

          7. Total bilirubin &gt; 2 fold the institutional upper limit unless considered to be due to
             organ involvement by the leukemia or to M. Gilbert / M. Meulengracht

          8. Concurrent severe diseases which exclude the administration of therapy

          9. Past history of acute or chronic pancreatits

         10. Patients unwilling or unable to comply with the protocol.e branch block; Right bundle
             branch block plus left anterior hemiblock, bifascicular block; Use of a
             ventricular-paced pacemaker; congenital long QT syndrome

               -  History of or presence of clinically significant ventricular or atrial
                  tachyarrhythmias

               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)

               -  QTcF&gt;450 msec on screening ECG. If QTc &gt; 450 msec and electrolytes are not within
                  normal ranges before nilotinib dosing, electrolytes should be corrected and then
                  the patient rescreened for QTcF criterion.

               -  Myocardial infarction with 12 months prior to starting nilotinib

               -  Other clinical significant heart disease (e.g. unstable angina, congestive heart
                  failure, uncontrolled hypertension)

                    -  Patients with a history of another primary malignancy that is currently
                       clinically significant or currently requires active intervention

                    -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing
                       is not mandatory) or known infection with Hepatitis B or C

                    -  Treatment with any, other investigational agent or participating in another
                       trial within 30 days prior to entering this study

                    -  Inadequate hepatic functions defined as ASAT or ALAT &gt; 2,5 times the
                       institutional upper limit of normal or &gt; 5 times ULN if considered due to
                       leukemia

                    -  Total bilirubin &gt; 2 fold the institutional upper limit unless considered to
                       be due to organ involvement by the leukemia or to M. Gilbert / M.
                       Meulengracht

                    -  Concurrent severe diseases which exclude the administration of therapy

                    -  Past history of acute or chronic pancreatits

                    -  Patients unwilling or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Pfeifer, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence cedex 1</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens - Hôpital Sud</name>
      <address>
        <city>AMIENS Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>ANGERS Cedex 09</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil Cedex</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>BESANÇON Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest - Hôpital Morvan</name>
      <address>
        <city>BREST Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;CHU Cote de nacre &quot;</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Dijon</name>
      <address>
        <city>DIJON Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Versailles - Hôpital André Mignot</name>
      <address>
        <city>LE CHESNAY Cedex</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier de l'Institut Catholique de Lille, hôpital Saint-Vincent</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>LILLE Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C H U de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>LIMOGES Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>MEAUX Cedex</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi</name>
      <address>
        <city>MONTPELLIER Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse - Hôpital Emile Muller</name>
      <address>
        <city>MULHOUSE Cedex</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu, Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital l'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans - Hôpital La Source</name>
      <address>
        <city>ORLEANS Cedex</city>
        <zip>45032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Saint Louis</name>
      <address>
        <city>PARIS Cedex 10</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>PARIS cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Necker</name>
      <address>
        <city>PARIS Cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Perpignan - Hôpital Saint-Jean</name>
      <address>
        <city>PERPIGNAN cedex 09</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>PESSAC Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital La Milétrie</name>
      <address>
        <city>POITIERS Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Région d'Annecy</name>
      <address>
        <city>Pringy Cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hôpital Robert Debré</name>
      <address>
        <city>REIMS Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes, Hôpital Pontchaillou</name>
      <address>
        <city>RENNES Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel, Rouen</name>
      <address>
        <city>Rouen Cedex 1</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de La Réunion - Hôpital Félix Guyon</name>
      <address>
        <city>SAINT DENIS Cedex</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg - Hôpital Hautepierre</name>
      <address>
        <city>STRASBOURG Cedex</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Sainte Anne</name>
      <address>
        <city>TOULON Cedex 9</city>
        <zip>83041</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Institut Universitaire du Cancer (CHU de Toulouse - Hôpital Purpan)&quot;</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hôpital Bretonneau</name>
      <address>
        <city>TOURS Cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valenciennes</name>
      <address>
        <city>VALENCIENNES Cedex</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hôpital Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Frankfurt, Medical Dept. II</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Münster</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig, José-Carreras-Haus</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol (ICO - Badalona)</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre (Madrid)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío (Sevilla)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe (Valencia)</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.uct-frankfurt.de/content/studien/studienregister/zu_den_studien/index_ger.html</url>
    <description>Trial register of University Cancer Center Frankfurt, additional trial information</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Heike Pfeifer</investigator_full_name>
    <investigator_title>Dr.med.</investigator_title>
  </responsible_party>
  <keyword>Philadelphia chromsome</keyword>
  <keyword>BCR-ABL</keyword>
  <keyword>ALL</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>Tasigna</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

